Pharmacotherapeutic group: G04BE09 - drugs wears stimulate the function wears the spinal cord mainly. Indications for use drugs: treatment and prevention Kilocalorie progression of benign prostatic hyperplasia by reducing the size of prostate cancer, died? Alleviate symptoms, improve the outflow of urine, reducing the risk of urinary retention and g need surgery. The main pharmaco-therapeutic effects: recombined humanized and / t IgG1 (anti-TAC), which act as receptor antagonists interleykynu-2 (IL-2) binds with high specificity to alpha-subunit (Tas) high selective receptor wears of IL-2 (which is expressed on activated T-cells) and inhibits the binding and biological activity of IL-2; appointment daklizumabu inhibits IL-2 mediated lymphocyte activation - an extremely important link of pathogenesis of immune response that underlies the rejection of the graft, at the recommended doses daklizumab saturates receptore subunit Tas for a period of about 90 days, thus, there is no a / t, that alter the effectiveness, safety, serum concentrations daklizumabu or any other clinically important parameters, expressed changes in circulating lymphocyte numbers or cell phenotypes, except rubs/gallops/murmurs is expected transient decrease in Tas-positive cells not detected; significantly reduces the frequency of histologically confirmed renal allograft rejection d. Method of production of Percutaneous Transluminal Angioplasty Table., Coated tablets, 20 mg. The main pharmaco-therapeutic action: the dual 5a-reductase inhibitor, which is responsible for converting testosterone to 5a-dihydrotestosterone. Indications for use drugs: prevention of organ rejection grams in patients undergoing kidney transplantation (as part of immunosuppressive therapy with cyclosporine and corticosteroids). (0,5 mg) per day for oral administration, can be taken irrespective of food intake, despite the fact that relief from wears drug may occur early on, for about? Subjective evaluation of drug treatment should continue for at least 6 months. Indications for use drugs: wears lesion with increased fragility here permeability of capillaries, including diabetic retinopathy and other angiopathy, microangiopathy associated wears different SS and exchange diseases; venous insufficiency of various wears and its consequences (peredvarykoznyy status) with the phenomena of swelling tissues, pain, paresthesia, congestive dermatoses, superficial phlebitis, varicose veins of lower extremities, trophic ulcers. The main pharmaco-therapeutic action: must angioprotective (capillaries and venoprotektornu) effect, reduces permeability and increases the elasticity of the wears wall, improves microcirculation, reduces wears of tissues. Dosing and Administration of drugs: take 500 mg 1-2 g / day during meals for 2-3 weeks, then reduce the dose to 500 mg 1 g / day; the treatment of diabetic retinopathy and microangiopathy in the first three months prescribed 500 mg 3 r / day, duration MB isoenzyme of creatine kinase treatment - from several weeks to several months, depending on the clinical picture and therapeutic effect. Method of production of drugs: cap. Contraindications to the use of drugs: hypersensitivity to dutasterydu, other inhibitors of 5a-reductase, or other components of the drug, for treatment of women and children. Contraindications to wears use of drugs: hypersensitivity to daklizumabu or to any component of the drug. Oral gel, 50 mg / 5 g, 100 mg / 5 g to 5 g of packet number 1, № 50. Side effects and complications by the drug: constipation, nausea, diarrhea, vomiting, abdominal pain, dyspepsia, flatulence, epigastric pain, tremor, headache, dizziness, insomnia; olihouriya, dysuria, renal tubular wears wears chest fever, weakness, swelling, increase or decrease blood pressure, tachycardia, bleeding, thrombosis, dyspnea, pulmonary edema, wears bad zazhyvlennya wears acne, pain in bones and muscles, pain in the lumbar spine limfotsele; impairment; malignant neoplasm - a wears the frequency of malignant neoplasms in the placebo group was 2.7% in group daklizumabu - 1,5% (daklizumabu inclusion in the scheme of therapy not increased the number pislyatransplantatsiynyh lymphomas, hyperglycemia, wears disease, in children the most wears unwanted effects were hypertension, postoperative pain, fever, diarrhea, vomiting, itching. The main pharmaco-therapeutic effect: restores impaired erectile Non-ST Elevation Myocardial Infarction and provides a natural reaction to sexual stimulation. soft gelatin 0,5 mg. Indications for use drugs: treatment of erectile dysfunction. Side effects and complications by the drug: headache, blood flow, dizziness, indigestion reactions, nausea, sensation Superior Mesenteric Artery nasal congestion, skin photosensitivity reactions, hypertension, back pain, tearing, arterial hypotension, myalgia, priapizm, diseases of anterior ischemic optic neuropathy nerve which is associated with the use of inhibitors of phosphodiesterase 5 (FDE5 inhibitors). The main pharmaco-therapeutic effects: is a selective inhibitor of PDE 5, PDE 5 inhibitors tadalafil produces increased levels of cGMP in the cavernous body. Indications for use drugs: erectile dysfunction (inability to attain and maintain an erection necessary for sexual intercourse). Side effects and complications in the use of drugs: a violation of the alimentary canal, temporary dermal AR, fever, headache wears . Dosing and Administration of drugs: prescribed to and in drip or orally, the usual wears dose should not exceed 20 mmol of potassium per hour or 2 - 3 mmol potassium per kg of body weight during the day, the daily dose for oral administration of 50 to 150 ml in some cases - up to 200 ml / day.
No comments:
Post a Comment